Intratumoral administration of CD1c (BDCA-1)(+) and CD141 (BDCA-3)(+) myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial

BACKGROUND: Intratumoral (IT) myeloid dendritic cells (myDCs) play a pivotal role in initiating antitumor immune responses and relicensing of anti-tumor cytotoxic T lymphocytes within the tumor microenvironment. Talimogene laherparepvec (T-VEC) induces immunogenic cell death, thereby providing matur...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwarze, Julia Katharina, Tijtgat, Jens, Awada, Gil, Cras, Louise, Vasaturo, Angela, Bagnall, Christopher, Forsyth, Ramses, Dufait, Inès, Tuyaerts, Sandra, Van Riet, Ivan, Neyns, Bart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486335/
https://www.ncbi.nlm.nih.gov/pubmed/36113895
http://dx.doi.org/10.1136/jitc-2022-005141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486335/
https://www.ncbi.nlm.nih.gov/pubmed/36113895
http://dx.doi.org/10.1136/jitc-2022-005141

Ejemplares similares